| Abstract |
In a phase II clinical (screening) trial, Cytembena has induced 20% objective regressions in uterus cervix carcinoma. This agent did not induce any myelosuppressive toxicity. |
| Authors | |
| Journal | Biomedicine / [publiee pour l'A.A.I.C.I.G.]
(Biomedicine)
Vol. 26
Issue 6
Pg. 392-5
(Dec 1977)
ISSN: 0300-0893 [Print] France |
| PMID | 342004
(Publication Type: Clinical Trial, Journal Article)
|
| Chemical References |
|
| Topics |
- Acrylates
(adverse effects, therapeutic use)
- Adult
- Aged
- Clinical Trials as Topic
- Drug Evaluation
- Female
- Humans
- Male
- Middle Aged
- Neoplasms
(drug therapy)
|
